United Therapeutics (UTHR) Amortizatization of Intangibles (2009 - 2016)
United Therapeutics' (UTHR) quarterly Amortizatization of Intangibles came in at -$100000.0 in Q2 2016, up 75.0% year-over-year from -$57142.9 in Q3 2015, and up 50.0% quarter-over-quarter from -$200000.0 in Q1 2016.
Powered by 
Analysis
United Therapeutics (UTHR) Amortizatization of Intangibles (2009 - 2016) Analysis & Trends
United Therapeutics has disclosed Amortizatization of Intangibles across 8 years of filings, most recently posting -$100000.0 for Q2 2016.
- In Q2 2016, Amortizatization of Intangibles rose 75.0% year-over-year to -$100000.0; the TTM figure through Jun 2016 stood at -$1.0 million (up 71.67% YoY), while the FY2015 annual figure was -$2.1 million, up 59.24% from the prior year.
- Amortizatization of Intangibles came in at -$100000.0 for Q2 2016 at United Therapeutics, up from -$200000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of -$100000.0 in Q2 2016 to a low of -$1.6 million in Q1 2014.
- Average Amortizatization of Intangibles over 5 years is -$931555.6, with a median of -$1.0 million recorded in 2013.
- Year-over-year, Amortizatization of Intangibles slumped 59.44% in 2014 and jumped 80.0% in 2016.
- Over 5 years, Amortizatization of Intangibles stood at -$1.3 million in 2012, then declined by 10.3% to -$1.4 million in 2013, then increased by 27.8% to -$1.0 million in 2014, then jumped by 74.32% to -$266000.0 in 2015, then soared by 62.41% to -$100000.0 in 2016.
- Per Business Quant data, the three most recent Amortizatization of Intangibles figures were -$100000.0 in Q2 2016, -$200000.0 in Q1 2016, and -$266000.0 in Q4 2015.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.47 Bn | 624.71 Bn | 17.26 Bn | - |
| 2 | AbbVie | 439.99 Bn | 433.42 Bn | 12.70 Bn | - |
| 3 | Merck | 365.45 Bn | 358.31 Bn | 12.21 Bn | 984.00 Mn |
| 4 | Novartis Ag | 266.57 Bn | 258.88 Bn | 11.24 Bn | - |
| 5 | Pfizer | 159.03 Bn | 147.33 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 44.23 Bn | 44.23 Bn | - | 4.33 Mn |
| 8 | Incyte | 25.32 Bn | 20.79 Bn | 1.57 Bn | - |
| 9 | United Therapeutics | 21.44 Bn | 18.77 Bn | 683.80 Mn | - |
| 10 | Neurocrine Biosciences | 15.52 Bn | 15.13 Bn | 935.80 Mn | 900,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2016 | -100,000.00 |
| Mar 31, 2016 | -200,000.00 |
| Dec 31, 2015 | -266,000.00 |
| Sep 30, 2015 | -466,000.00 |
| Jun 30, 2015 | -400,000.00 |
| Mar 31, 2015 | -1.00 Mn |
| Dec 31, 2014 | -1.04 Mn |
| Sep 30, 2014 | -1.21 Mn |
| Jun 30, 2014 | -1.38 Mn |
| Mar 31, 2014 | -1.60 Mn |
| Dec 31, 2013 | -1.44 Mn |
| Sep 30, 2013 | -1.03 Mn |
| Jun 30, 2013 | -1.03 Mn |
| Mar 31, 2013 | -1.01 Mn |
| Dec 31, 2012 | -1.30 Mn |
| Sep 30, 2012 | -970,000.00 |
| Jun 30, 2012 | -1.20 Mn |
| Mar 31, 2012 | -1.13 Mn |
| Dec 31, 2011 | -1.07 Mn |
| Sep 30, 2011 | -969,000.00 |